XSTOBACTIb
Market cap119mUSD
Dec 23, Last price
37.90SEK
1D
0.53%
1Q
-37.87%
Jan 2017
124.26%
IPO
17.70%
Name
Bactiguard Holding AB
Chart & Performance
Profile
Bactiguard Holding AB (publ), a medical device company, engages in the development and supply of infection prevention solutions in Sweden and internationally. Its infection prevention solutions reduce the risk of healthcare associated infections and the use of antibiotics. The company's products portfolio of urinary catheters, endotracheal tubes, and central venous catheters reduces the risk of infections in the urinary tract, the respiratory tract, and the bloodstream. Its product portfolio consists of Bactiguard infection protection (BIP) Foley Catheter, an indwelling urinary catheter that reduces microbial adhesion; BIP Central Venous Catheter and BIP Endotracheal Tube, which reduces the risk of biofilm formation and infection; BIP Endotracheal Tube Evac, a tube that combines the subglottic secretion drainage with coating to reduce microbial adhesion; and BIP Foley TempSensor, an indwelling urinary catheter that offers surveillance and infection prevention. The company's products also include Bactiguard Wound Care and Hydrocyn aqua advanced wound care, a wound wash, debridement, and irrigation solution for acute, chronic, and infected wounds; surgical sutures comprise non-absorbable, natural absorbable, synthetic absorbable, and specialty sutures; VigiMesh, a sterile, non-absorbable, and knitted polypropylene monofilament mesh material for tissue reinforcement used in hernia repair; and Hydrocyn aqua advanced disinfectant, a non-alcoholic disinfectant for skin and surfaces to kill bacteria, virus, and fungi. In addition, it offers ZNN Bactiguard, an orthopedic trauma implants with infection prevention technology; and Aniocyn, a wound and skin care products for dogs, cats, horses, and other pets. Bactiguard Holding AB (publ) was founded in 2005 and is headquartered in Tullinge, Sweden.
Valuation
Title SEK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | 2014‑12 | |
Income | ||||||||||
Revenues | 203,990 -8.75% | 223,560 31.90% | 169,486 -1.64% | |||||||
Cost of revenue | 68,978 | 158,925 | 125,181 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | 135,012 | 64,635 | 44,305 | |||||||
NOPBT Margin | 66.19% | 28.91% | 26.14% | |||||||
Operating Taxes | (8,772) | (6,978) | (4,479) | |||||||
Tax Rate | ||||||||||
NOPAT | 143,784 | 71,613 | 48,784 | |||||||
Net income | (138,382) 161.71% | (52,877) -10.03% | (58,773) 53.10% | |||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | 228,000 | |||||||||
BB yield | -3.94% | |||||||||
Debt | ||||||||||
Debt current | 190,793 | 10,915 | 9,652 | |||||||
Long-term debt | 96,836 | 287,218 | 305,605 | |||||||
Deferred revenue | 149,583 | 180,663 | ||||||||
Other long-term liabilities | 5,284 | (179,265) | (180,663) | |||||||
Net debt | 143,708 | 99,096 | 95,996 | |||||||
Cash flow | ||||||||||
Cash from operating activities | (52,331) | 3,062 | 7,256 | |||||||
CAPEX | (7,189) | (10,918) | (7,294) | |||||||
Cash from investing activities | (8,609) | (10,918) | (7,295) | |||||||
Cash from financing activities | (11,835) | (13,892) | 205,827 | |||||||
FCF | 182,595 | 85,490 | 81,707 | |||||||
Balance | ||||||||||
Cash | 123,217 | 197,727 | 217,587 | |||||||
Long term investments | 20,704 | 1,310 | 1,674 | |||||||
Excess cash | 133,722 | 187,859 | 210,787 | |||||||
Stockholders' equity | (576,647) | (434,971) | (385,389) | |||||||
Invested Capital | 1,168,208 | 1,139,697 | 1,174,799 | |||||||
ROIC | 12.46% | 6.19% | 4.56% | |||||||
ROCE | 22.82% | 8.80% | 5.56% | |||||||
EV | ||||||||||
Common stock shares outstanding | 35,044 | 35,044 | 35,044 | |||||||
Price | 61.80 -44.02% | 110.40 -33.09% | 165.00 15.38% | |||||||
Market cap | 2,165,712 -44.02% | 3,868,845 -33.09% | 5,782,241 20.54% | |||||||
EV | 2,309,420 | 3,967,941 | 5,882,078 | |||||||
EBITDA | 174,614 | 113,875 | 91,309 | |||||||
EV/EBITDA | 13.23 | 34.84 | 64.42 | |||||||
Interest | 13,528 | 8,697 | 8,373 | |||||||
Interest/NOPBT | 10.02% | 13.46% | 18.90% |